Terra Nova Asset Management LLC Sells 356 Shares of Stryker Corporation $SYK

Terra Nova Asset Management LLC trimmed its position in Stryker Corporation (NYSE:SYK) by 4.2% in the 2nd quarter, Holdings Channel.com reports. The fund owned 8,043 shares of the medical technology company’s stock after selling 356 shares during the quarter. Stryker makes up approximately 2.2% of Terra Nova Asset Management LLC’s portfolio, making the stock its 14th biggest position. Terra Nova Asset Management LLC’s holdings in Stryker were worth $3,182,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in SYK. Mid American Wealth Advisory Group Inc. acquired a new stake in shares of Stryker in the 2nd quarter worth $26,000. Sachetta LLC raised its stake in Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after buying an additional 27 shares during the last quarter. Ridgewood Investments LLC boosted its holdings in Stryker by 48.4% in the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after acquiring an additional 30 shares in the last quarter. Ransom Advisory Ltd purchased a new stake in shares of Stryker during the first quarter worth about $37,000. Finally, MTM Investment Management LLC acquired a new position in shares of Stryker during the second quarter valued at about $38,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of NYSE SYK opened at $364.39 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The firm’s 50 day simple moving average is $370.25 and its 200-day simple moving average is $380.91. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The stock has a market capitalization of $139.35 billion, a price-to-earnings ratio of 48.26, a PEG ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. During the same period in the prior year, the firm posted $2.87 earnings per share. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Redburn Partners set a $420.00 target price on shares of Stryker in a research report on Thursday, September 18th. Rothschild Redb raised shares of Stryker to a “hold” rating in a report on Thursday, September 18th. Rothschild & Co Redburn began coverage on Stryker in a research report on Thursday, September 18th. They issued a “neutral” rating and a $420.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $448.00 price target on shares of Stryker in a research report on Friday, November 14th. Finally, Wells Fargo & Company increased their price objective on shares of Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a research note on Friday, November 14th. Thirteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $434.37.

Insider Activity at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 1,953 shares of the stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total transaction of $713,801.97. Following the transaction, the chief accounting officer owned 2,833 shares in the company, valued at approximately $1,035,433.17. This represents a 40.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the sale, the director directly owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 522,453 shares of company stock worth $185,516,867 in the last 90 days. Corporate insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.